Image Source: Pexels

Ventas Inc. has bagged an ‘Overweight’ rating from Wells Fargo post the release of its financial results for Q1 2023. The company released its earnings on May 8, 2023, which prompted many brokers to review their recommendations on the stock.

Ventas is primarily an REIT company with a diversified healthcare portfolio. The properties held by Ventas are utilised across various businesses such as senior housing, medical office, hospitals and life science.

The company’s revenue during Q1 2023 witnessed a significant drop. However, despite these results, VTR stock garnered a ‘Buy’ rating from majority of the analysts. As per data available on EODHD/Others, four analysts have given VTR a ‘Strong Buy’ rating, eleven analysts have given it a ‘Buy’ rating and seven analysts have given it a ‘Hold’ rating. Alternatively, none of the analysts have given it a ‘Sell’ or ‘Strong Sell’ rating.

Image source: ©2023 Kalkine®; Data source: EODHD/Others

The price target for Ventas

The consensus mean price target for Ventas stands at US$ 52.17, which is 11.3% higher than its closing price on May 9, 2023, of US$ 46.86. Wells Fargo has given VTR a price target of US$ 50. This is 6.7% higher than its closing price on May 9, 2023.

Among other brokers, Raymond James also revised its recommendation on the stock on May 8, 2023, after the release of the company’s earnings. The broker gave Ventas an ‘Outperform’ rating, with a price target of US$ 55, indicating an upside potential of 17.37% over the closing price of US$ 46.86 on May 9, 2023.

Image Source: EODHD/Others

VTR shares closed at US$ 46.86 on May 9, 2023. It reached its 52-week high of US$ 58.24 on May 26, 2022.

Ventas’ Financial Statements

For the three months ended March 31, 2022, Ventas reported a net income of US$ 18.91 million. However, for the same quarter in 2022, the company reported a net income of US$ 40.59 million. This highlights a major dip in income during Q1 2023 as the global economy heads for a recession.

The total revenue for the quarter was US$ 704.99 million, while EBITDA was US$ 419.98 million. This marked a slip from both Q4 2022 and Q1 2022. Additionally, the operating cash flow during Q1 2023 was US$ 242.82 million.